斑块状银屑病患者从司库奇尤单抗转换为依奇珠单抗治疗的疗效与安全性：一项多中心回顾性研究
Efficacy and Safety of Intra-Class Switching from Ixekizumab to Secukinumab in Patients with Plaque Psoriasis: A Multicenter Retrospective Study.
作者信息
Bernardini Nicoletta, Dattola Annunziata, Rossi Raimondo, Pagnanelli Gianluca, Amerio Paolo, Atzori Laura, Mugheddu Cristina, Lora Viviana, Giordano Domenico, Guacci Lucia Finistauri, Persechino Severino, Richetta Antonio Giovanni, Skroza Nevena, Potenza Concetta
机构信息
Dermatology Unit "Daniele Innocenzi", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
出版信息
J Pers Med. 2024 Dec 22;14(12):1169. doi: 10.3390/jpm14121169.
the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. this study included 11 patients (6 male, 5 female) who had previously received ixekizumab and then were switched to secukinumab. Patients' PASI, DLQI, and pain VAS (in those with psoriatic arthritis) were evaluated at weeks 16, 24, 54, and 98. PASI-90 was reached in 10 (91%) cases at week 24. One patient experienced secondary failure to secukinumab at week 98. No adverse events were reported. overall, the majority of patients experienced a favorable response to secukinumab, suggesting that it may be an effective treatment option for patients with an inadequate response or loss of efficacy to ixekizumab.
本多中心回顾性研究旨在评估斑块状银屑病患者中白细胞介素-17A（IL-17A）抑制剂类间转换的疗效和安全性，具体是从司库奇尤单抗转换为依奇珠单抗。本研究纳入了11例患者（6例男性，5例女性），这些患者先前接受过依奇珠单抗治疗，随后转换为司库奇尤单抗治疗。在第16周、24周、54周和98周对患者的银屑病面积和严重程度指数（PASI）、皮肤病生活质量指数（DLQI）以及（银屑病关节炎患者的）疼痛视觉模拟量表（VAS）进行评估。在第24周时，10例（91%）患者达到了PASI-90。1例患者在第98周时出现对司库奇尤单抗的继发治疗失败。未报告不良事件。总体而言，大多数患者对司库奇尤单抗有良好反应，这表明它可能是对依奇珠单抗反应不足或疗效丧失的患者的一种有效治疗选择。
Zotero 插件